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Abstract: Reduced-intensity/reduced-toxicity conditioning and allogeneic T-cell replete hematopoietic
stem cell transplantation are curative in patients with hemophagocytic lymphohistiocytosis (HLH). Un-
stable donor chimerism (DC) and relapses are clinical challenges . We examined the effect of a reduced-
intensity conditioning regimen based on targeted busulfan to enhance myeloid DC in HLH. The Eu-
ropean Society for Bone and Marrow Transplantation-approved reduced-intensity conditioning protocol
comprised targeted submyeloablative IV busulfan, IV fludarabine, and serotherapy comprising IV alem-
tuzumab (0.5-0.8 mg/kg) for unrelated-donor and IV rabbit anti-T-cell globulin for related-donor trans-
plants. We assessed toxicity, engraftment, graft-versus-host disease (GHVD), DC in blood cell subtypes,
and overall survival/event-free survival. Twenty-five patients from 7 centers were treated (median age,
0.68 year). The median total dose and cumulative area under the curve of busulfan was 13.1 mg/kg (6.4-
26.4) and 63.1 mg/L × h (48-77), respectively. Bone marrow, peripheral blood stem cell, or cord blood
transplants from HLA-matched related (n = 7) or unrelated (n = 18) donors were administered. Donor
cells engrafted in all patients (median: neutrophils d+20/platelets d+28). At last follow-up (median, 36
months; range, 8-111 months), the median DC of CD15+ neutrophils, CD3+ T cells, and CD16+56+
natural killer cells was 99.5% (10-100), 97% (30-100), and 97.5% (30-100), respectively. Eight patients
(32%) developed sinusoidal obstruction syndrome, resolving after defibrotide treatment. The 3-year over-
all survival and event-free survival rates were both 100%. None of the patients developed acute grade III
to IV GHVD. Limited chronic GVHD was encountered in 4%. This regimen achieves excellent results
with stable DC in patients with HLH.
DOI: https://doi.org/10.1182/bloodadvances.2020001748
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free survival in HLH.
• After a median follow-
up of 3 years, satisfac-
tory DC on myeloid and
T cells, no graft failures,
and a low rate of
chronic GHVD were
observed.
Reduced-intensity/reduced-toxicity conditioning and allogeneic T-cell replete hematopoietic
stem cell transplantation are curative in patients with hemophagocytic lymphohistiocytosis
(HLH). Unstable donor chimerism (DC) and relapses are clinical challenges . We examined
the effect of a reduced-intensity conditioning regimen based on targeted busulfan to
enhance myeloid DC in HLH. The European Society for Bone and Marrow
Transplantation–approved reduced-intensity conditioning protocol comprised targeted
submyeloablative IV busulfan, IV fludarabine, and serotherapy comprising IV alemtuzumab
(0.5-0.8 mg/kg) for unrelated-donor and IV rabbit anti–T-cell globulin for related-donor
transplants. We assessed toxicity, engraftment, graft-versus-host disease (GHVD), DC in
blood cell subtypes, and overall survival/event-free survival. Twenty-five patients from 7
centers were treated (median age, 0.68 year). The median total dose and cumulative area
under the curve of busulfan was 13.1 mg/kg (6.4-26.4) and 63.1 mg/L 3 h (48-77),
respectively. Bone marrow, peripheral blood stem cell, or cord blood transplants from
HLA-matched related (n 5 7) or unrelated (n 5 18) donors were administered. Donor cells
engrafted in all patients (median: neutrophils d120/platelets d128). At last follow-up
(median, 36 months; range, 8-111 months), the median DC of CD151 neutrophils, CD31
T cells, and CD161561 natural killer cells was 99.5% (10-100), 97% (30-100), and 97.5%
(30-100), respectively. Eight patients (32%) developed sinusoidal obstruction syndrome,
resolving after defibrotide treatment. The 3-year overall survival and event-free survival
rates were both 100%. None of the patients developed acute grade III to IV GHVD. Limited
chronic GVHD was encountered in 4%. This regimen achieves excellent results with stable
DC in patients with HLH.
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Introduction
Primary hemophagocytic lymphohistiocytosis (HLH) comprises
a group of genetically determined, life-threatening immune disor-
ders with an estimated incidence of 1.2 per million children per
year.1Deficiencies in the content, assembly, trafficking, or release of
cytolytic granules in T cells and natural killer (NK) cells account for
the majority of patients, whereas molecular diagnosis may remain
unsolved in some individuals with presumed primary HLH.2,3 To
date, mutations in 4 different genes (PRF1, UNC13D, STXBP2,
and STX11) have been found causative for familial HLH (FHL).
Mutations in other genes (RAB27A, LYST, SH2D1A, BIRC4,
HAVCR2 (TIM-3), NLRC4, CD48, CDC42, and AP3B3A) were
shown to be responsible for primary immunodeficiency and auto-
inflammatory syndromes in which HLH is a prominent clinical
feature.3-8 Viral infections are important triggers of HLH episodes in
patients with a genetic predisposition. Persistent, uncontrolled
activation of innate and adaptive immunity in secondary lymphoid
organs and liver with cytokine hypersecretion ultimately results in
hemorrhage, multiorgan failure, and death.2,4,9 The clinical and
laboratory features of HLH include fever, hepatosplenomegaly,
pancytopenia, hyponatremia, hyperlipidemia, hyperferritinemia, and
severe coagulopathy. Timely diagnosis, systemic/intrathecal treatment
with immunosuppressive/anti-inflammatory drugs, and specific treat-
ment of triggering infections, pancytopenia, and coagulopathy are
able to halt disease progression in some patients until definitive cure
by allogeneic hematopoietic stem cell transplantation (HSCT).10-12
Advances in the pathophysiological understanding have led
to improved treatment protocols to achieve remission of HLH
episodes.13,14 The analysis of both prospective HLH-1994/HLH-
2004 trials showed that only 60% of patients achieved complete
remission (CR), and disease progression remained the primary
cause of death in patients without HSCT within 12 months of
disease onset.15-20 Therapeutic strategies to avoid etoposide as the
most toxic component of HLH-2004 comprise alemtuzumab13 or
emapalumab,21 which are currently being investigated to prove their
efficacy in inducing remission in HLH until HSCT. Currently,
allogeneic HSCT remains the only curative treatment modality in
HLH. This is mainly achieved by correction of cytotoxicity via
adoptive transfer and de novo production of healthy CD31 T cells
and NK cells of donor origin.17,22-29
For a long time, myeloablative conditioning regimens (MAC) based
on busulfan/cyclophosphamide (6 etoposide) have been consid-
ered as the standard of care for patients with HLH, even though
transplant-related morbidity and mortality were substantial (up to
64%).22,24,30-33 The introduction of reduced-intensity conditioning
(RIC) and reduced-toxicity conditioning protocols helped decrease
MAC-associated transplant-related morbidity and mortality; how-
ever, graft failure (GF), waning donor chimerism (DC),29,31,34
relapses of HLH,34 and acute/chronic graft-versus-host disease
(GHVD)35 remained issues of clinical concern. Because low DC
may predispose to disease recurrence,34 posttransplant interven-
tions, including early tapering of immunosuppression, administration
of donor lymphocyte infusion (DLI), and stem cell boosts, have been
increasingly used to augment DC after RIC transplantations. These
approaches clearly increased the risk of inducing acute/chronic
GHVD, however, with inacceptable implications on quality of life
and long-term outcome.12,29,31,35
A RIC regimen based on targeted busulfan showed excellent
engraftment and low toxicity features in high-risk pediatric and adult
patients with chronic granulomatous disease (CGD).36 The current
study examined the effects of this RIC regimen in patients with
primary HLH undergoing HSCT with HLA-matched donors within
a collaborative multicenter study of the Inborn Errors Working Party




From June 2009 to June 2019, seven European pediatric SCT
centers agreed to use the protocol in patients with HLH.
Functional and molecular evaluation for primary HLH was based on
a standardized algorithm (supplemental Data A). For induction of
remission, modified HLH-200417 and/or alemtuzumab-based pro-
tocols were administered. Central nervous system (CNS) in-
volvement and HLH remission status (complete remission [CR];
partial remission) were defined according to HLH-2004. In line with
the tenets of the Declaration of Helsinki, parents and patients
provided written informed consent for participation in this trans-
plantation protocol, which is part of the IEWP EBMT guidelines to
treat high-risk primary immunodeficiency patients.36
Conditioning regimen, transplantation, and
GHVD prophylaxis
RIC conditioning was administered as previously described36
comprising IV fludarabine (30 mg/m2 or in infants ,9 kg body
weight [bw] 1.2 mg/kg per dose on d-8 to d-3) and pharmacokinetic-
adjusted targeted IV busulfan. Busulfan was administered from d-5
to d-2. The recommended infusion modality was twice daily over
3 or 4 hours. Four-times-daily administration over 1 hour was also
accepted. The modified starting doses of busulfan depended on
a weight-based protocol introduced by Bartelink et al.37,38 The
kinetic parameters, including the cumulative area under the curve
(cAUC) of busulfan, was calculated by using the two-compartment
WinNonlin pharmacokinetic program.37 To prevent GF (previously
5% in patients with CGD), the cAUC for busulfan was recom-
mended to be targeted toward the upper part of the previously
reported busulfan exposure (45-65 mg/L 3 h)36 (supplemental
Data B).
Patients with a 9-10/10-HLA–matched unrelated donor (MUD) or
9/10-HLA–matched cord blood (9/10/UCB) underwent serother-
apy with IV alemtuzumab (0.17-0.27 mg/kg bw per dose) from d-8
to d-6. To reduce the risk of GVHD by grafts of HLA single-
mismatched unrelated donors unwilling to donate bone marrow,
study centers were permitted to perform a CD341 HSC-positive
selection in peripheral blood stem cell (PBSC) grafts (CliniMACS
technique, Miltenyi Biotec) together with a CD31 T-cell addback.
The CD31 content of the graft was adjusted to bone marrow
conditions by a CD31 T-cell reduction of approximately one log.39
Serotherapy included rabbit anti-thymocyte globulin (Thymoglobulin
[Sanofi-Aventis]; 2.5 mg/kg bw IV per dose on d-5 to d-3) or
anti–T-lymphocyte globulin against Jurkat-cells (Grafalon [Neovii
Pharmaceuticals AG]; 10 mg/kg bw IV per dose on d-4 to d-1) for
6/6-HLA–matched related sibling/related (MSD/MRD) donor trans-
plants and 10/10-HLA–matched unrelated cord blood (10/10/
UCB) donor transplants (Table 1). IV cyclosporin A (CSA) was
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started at d-3 to maintain trough levels of 200 mg/L. In case of
absent GVHD, oral CSA was administered until d1120 and
tapered until d1180. IV mycophenolate-mofetil was started at day
0 (3 3 400 mg/m2), later continued orally for 60 to 100 days.36
To prevent sinusoidal obstruction syndrome (SOS), prophylactic
measures included IV defibrotide (DF; total 25 mg/kg per day,
4 times a day) or IV heparin (total 100 U/kg per day continuous
infusion) and/or intravenous N-acetyl cysteine (total 200 mg/kg,
twice daily), according to the center’s preference.40,41 Recom-
mended SOS treatment is IV DF42 starting immediately after
fulfillment of the modified Seattle criteria.42,43 The current pediatric
EBMT criteria were applied retrospectively to grade the SOS
severity.44 SOS diagnostics included abdominal sonography and
Doppler scan to detect inversed portal-venous flow for SOS
confirmation.40,42 In oxygen-dependent states, echocardiography
screens helped to exclude pulmonary hypertension.
GHVD was assessed according to the Glucksberg and National
Institutes of Health classifications. The severity of mucositis was
assessed according to the World Health Organization score.
Statistical analysis
The overall survival (OS), event-free survival (EFS; event 5 graft
failure with ,5% DC in whole blood or ,20% CD31 T cells),34
chronic GHVD–free survival, and neutrophil ($0.5 3 109/L) and
platelet ($ 503109/L) engraftment were described by using
Kaplan-Meier estimates; countable characteristics (eg, age, cell
dose, AUC of busulfan) by using medians and interquartile ratios
(IQRs); and comparisons by using two-tailed Student t tests. For
analyses, statistics, and graphics, GraphPad Prism (version 6.0a),
Microsoft Excel, and Word 2011 software were used.
Results
Patients
Twenty-two consecutive patients from 5 centers and 3 non-
consecutive patients from 2 centers have been treated according
the protocol. Transplantations were performed at a median age of
0.68 year (IQR, 0.42-3.07; range, 2 months-22 years). Twenty-three
patients had molecularly proven autosomal recessive HLH: 14
with FHL3 (UNC13D), 4 with FHL5 (STXBP2), 4 with X-linked
lymphoproliferative syndrome 1 (SH2D1A), and 1 with Chédiak-
Higashi syndrome (LYST) (Table 1). Extensive functional and
genetic analyses failed to clearly reveal causative mutations in 2
patients (supplemental Data C).
Pretreatment and complications before HSCT
Fifty-two percent (n 5 13) of patients received treatment to induce
remission of HLH episodes by administration of the HLH-2004
protocol. Of these, 38% (n 5 5) needed additional treatment of
remission induction that included IV infliximab or IV alemtuzumab.
Based on the aim of avoiding administration of VP-16, 36% (n 5 9)
received steroids, IV immunoglobulins, and/or IV alemtuzumab
instead of the HLH-2004 protocol for remission induction. Twenty-
four percent (n 5 6) with CNS involvement received intrathecal
methotrexate. Two patients with SAP deficiency presented ini-
tially with non-HLH symptoms: unique patient number 4 (UPN4)
developed acute demyelinating encephalomyelitis and was treated
with cyclophosphamide. UPN3 presented with malignant diffuse
large B-cell lymphoma and received anti-lymphoma chemotherapy.
Sixteen percent of patients (UPN1, UPN5, UPN19, and UPN20)
were diagnosed by using family history and had not experienced
HLH episodes before transplantation. At the time point of HSCT,
20% of patients (n5 5) were in partial remission, and 80% (n5 20)
were in CR (Table 1).
Therapeutic drug monitoring of busulfan
Ninety-six percent (n5 24) of patients received twice-daily busulfan
infusions except UPN23, who received a four-times-daily regimen.
Ninety-two percent (n 5 23) were targeted within the target range
for the cAUC (45-65 mg/L3 h,65%). Forty-three percent (n5 12)
were targeted around 65 mg/L 3 h. UPN11 and UPN23 were
slightly above the target range (73 and 77 mg/L 3 h); none was
below (Figure 1; Table 1). The median busulfan exposure was
63.1 mg/L 3 h (IQR, 56.02-65; range, 48-77 mg/L 3 h)
corresponding to 11 693 to 18757 mM 3 min. The median total
cumulative busulfan dose was 13.1 mg/kg (IQR, 11.4-16; range,
6.4-26.4).
Stem cell sources and graft composition
Bone marrow (68%; n 5 17), PBSC (24%; n 5 6), and CB (8%;
n 5 2) grafts were transfused. UPN17, UPN21, and UPN25
received PBSC grafts after CD341 HSC-positive selection and
CD31 T-cell addback (0.5-3.0 3 10 e7 CD31 T cells/kg).
Transplants comprised HSCs from MSD/MRD (n 5 7) and MUD
(n 5 18) donors, of which three were 9/10-HLA–matched and 15
were 10/10-HLA–matched and two 9/10-HLA–matched and
10/10-HLA–matched cords (Table 1). The median number of
CD341 HSCs infused was 8.6 (IQR, 5.6-13.7; range, 2.25-32.2) in
bone marrow/PBSC and 1.025 3 106/kg (0.9 and 1.15) in CB
grafts.
Toxicity, engraftment, chimerism, and
immune recovery
Toxicity. Mucositis was observed in 48% (n 5 12) of patients
and did not exceed grade II except in UPN3, UPN21, and UPN24
(grade III). DF prophylaxis was administered in 20% of patients
(n 5 5), and SOS developed in 32% (n 5 8) of patients. The SOS
incidence did not differ between patients with DF prophylaxis and
those without (20% vs 35%; P 5 .74). Six patients were classified
as having moderate SOS and 2 as having severe SOS.44 All
patients who developed SOS responded well to DF therapy, with
complete resolution of SOS. Three patients needed additional
procedures, including paracentesis to drain ascites, and one
required ventilator support (Table 2). None developed pulmonary
hypertension.33
Engraftment. The median time until donor neutrophil engraft-
ment was 20 days (IQR, 17-23; range, 11-31); the median time until
platelet engraftment was 28 days (IQR, 20-38; range, 11-74)
(Figure 2).
Chimerism. After a median follow-up time of 36 months (IQR,
22-52; range, 8-111), the median donor CD151 neutrophil
chimerism was 99.5% (IQR, 94-100; range, 10-100) with 18
patients $95%, 3 $90%, 3 between 58% and 73%, and 1 with
10%. The median donor CD31 T-cell chimerism was 97% (IQR, 87-
100; range, 30-100) with 13 patients $95%, 10 at 74% to 92%, 1
with 40%, and 1 with 30% DC. The median donor CD561 NK cell
chimerism was 97.5% (IQR, 87.75-100; range, 30-100; n 5 16)
with 10 $95% and 6 between 30% and 88%. There were no
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Table 1. Patient and transplant characteristics




































1 XLP1/SH2D1A M 16 y Family history N NA CR N/IVIG MUD/10/
10/BM
Alemtuzumab 0.5 2.1 6.4 59 23 21
2 XLP1/SH2D1A M 22 y HLH episode, IgG low
EBV-hepatitis/-CMP
N 1040 CR Y/steroids MSD/6/6/
PBSC
Thymoglobulin 7.5 2.4 9.7 53 17 14




Alemtuzumab 0.6 7.23 17 67 20 16
4 XLP1/SH2D1A M 3.8 y Developmental regression ADEM Y 14 PR N/IVIG, steroids, CY MUD/9/10/
BM
Alemtuzumab 0.6 15.3 26.4 54 24 74
5 CHS/LYST F 1 y Nystagmus, oculocutaneous
albinism
N* NA CR N/no treatment MUD/10/
10/BM
Alemtuzumab 0.5 2.7 12 64 23 38
6 FHL5/STXBP2 F 3 mo HLH episode, sepsis, mild renal
impairment




Alemtuzumab 0.5 13.4 14 53 17 38




Thymoglobulin 7.5 7 10 66 14 47
8 FHL5/STXBP2 M 4 mo HLH episode, hepatic/renal failure N 15 CR Y/HLH-2004 UCB/9/10/
cord
Alemtuzumab 0.6 1.15 7.2 63 24 30
9 FHL5/STXBP2 F 3 y Recurrent HLH episodes N 20 CR Y/HLH-2004 MUD/10/
10/BM
Alemtuzumab 0.5 2.25 17.3 55 22 34
10 FHL3/UNC13D M 10 mo HLH episode, cardiac effusion N 11 CR Y/HLH-2004 MUD/10/
10/BM
Alemtuzumab 0.6 8.6 15.6 64 20 17
11 FHL3/UNC13D M 5 mo HLH episode, focal seizures, NEC Y 11 CR Y/HLH-2004 MUD/10/
10/BM
Alemtuzumab 0.5 5.58 16 77 19 42




Alemtuzumab 0.6 10 16 65 28 14
13 FHL3/UNC13D F 9.25 y HLH episode, GBS Y 29 PR Y/HLH-2004 MRD/10/
10/BM
ATG-N 40 4.59 11.4 56 28 29
14 FHL3/UNC13D F 4 mo HLH episode, CMV1,
CMP, neurologically
handicapped
Y 12 PR Y/steroids UCB/10/
10/cord
Thymoglobulin 7.5 0.9 12.08 48 21 28
15 FHL3/UNC13D M 5 mo HLH episode, FTT Y 20 CR Y/HLH-2004 MSD/6/6/
BM
Thymoglobulin 7.5 32.2 19.04 63 11 37
16 FHL3/UNC13D M 7 mo HLH episode, polyserositis N 23 CR Y/HLH-2004 MUD/10/
10/BM
Alemtuzumab 0.6 5.55 13.1 68 18 29
17 FHL3/UNC13D F 3.5 y HLH episode, thrombosis
of the sinus sagittalis
superior
Y 19 CR Y/HLH-2004 MUD/9/10/
PBSC†
Alemtuzumab 0.6 13.95 12.4 62 15 11




Alemtuzumab 0.6 10.7 24.6 65 15 40
19 FHL3/UNC13D F 5 mo Family history N NA CR N/CSA MUD/10/
10/BM
Alemtuzumab 0.6 10 15.4 65 15 26
20 FHL3/UNC13D F 2 mo Family history N NA CR N/N MSD/6/6/
BM
Thymoglobulin 7.5 24.8 11.4 65 28 23
ADEM, acute disseminated encephalomyelitis; ANC, absolute neutrophil count; ATG-N, ATG-Neovii (Grafalon); AUC, area under the curve; BM, bone marrow; Bu, busulfan; bw, body weight; CMP, cardiomyopathy; Cum., cumulative; CY,
cyclophosphamide; D, days until engraftment; DLBCL, diffuse large B-cell lymphoma; F, female; FTT, failure to thrive; GBS, Guillain-Barré-Syndrome; IgG, immunoglobulin G; IVIG, intravenous immunoglobulin; M, male; MRD, HLA-matched
related donor; MSD, HLA-matched sibling donor; MUD, HLA-matched unrelated donor; N, no; NA, not applicable; NEC, necrotizing enterocolitis; PR, partial remission; tx, hematopoietic stem cell transplantation; UCB, unrelated cord blood; UPN,
unique patient number; wk, weeks; XLP1, X-linked lymphoproliferative syndrome 1; Y, yes.
*Neurological disease due to Chédiak-Higashi syndrome but not due to CNS involvement or HLH.





































































primary or secondary GFs. None received secondary cellular
treatments such as DLI, stem cell boosts, or second transplants.
None needed precocious tapering of immunosuppressive agents
due to decline in myeloid and lymphocyte DC until d1180
(Figure 3; supplemental Figure 1).
GHVD disease, immune reconstitution, complications
after HSCT, and clinical outcome
GHVD. Forty percent (n 5 10) of patients developed grade I to II
acute GHVD, affecting mainly the skin and responding well to
topical and/or systemic corticosteroids. None developed grade III to
IV GHVD (Table 2). UPN3 experienced acute relapsing grade II
acute GHVD of the skin. He responded well to extracorporeal
photopheresis, topical steroid, sirolimus, and ruxolitinib combination
treatment that could be reduced to ruxolitinib monotherapy. UPN17
developed localized lichenoid GHVD, which responded favorably to
mammalian target of rapamycin inhibitor treatment and topical
steroids, which could be stopped successfully. The other 24
patients became independent of immunosuppression within 4 to 10
months’ post-HSCT. All patients, except UPN3 who is currently
been treated with waning ruxolitinib doses, recovered with naive
CD41 T cells reaching normal age-related percentiles and
normalized B-cell function (data not shown).
Clinical outcome. At last follow-up (median, 36 months; range,
8-111 months), all 25 patients were alive and disease free
(Figure 4). None developed HLH relapses or progressive CNS
disease. Preexisting neurological impairment resolved (UPN13) or
remained unchanged (UPN4 and UPN14).
Two patients with STXBP2 mutations have persistent mild
gastrointestinal dysfunction with no need for parenteral nutrition
despite the absence of GHVD. UPN8 developed asymptomatic
Hashimoto’s thyroiditis. Patient UPN25 with HLH of unsolved
molecular origin (supplemental data C) developed knee arthritis that
has responded well to intra-articular steroid injections. She has
remained free of HLH and joint inflammation as of publication time.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Interindividual variability of busulfan exposure. Each symbol
denotes the cAUC (mg/L 3 h) in relation to the administered total cumulative dose
(mg/kg bw) of busulfan in patients aged ,1 year (squares), .1 year and ,4 years
(circles), and .4 years (triangles) of age. Filled symbols denote patients developing
SOS. The target submyeloablative cAUC (45-65 mg/L 3 h) is depicted in gray.
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1 Hep N 52 Alive 100 100 88 0 0 BK Hemorrhagic cystitis
2 Hep N 64 Alive 100 100 100 2 0 EBV Femur head necrosis
after 2 mo of steroids
due to transient acute
GHVD II of the liver
3 NAC N 16 Alive 100 100 100 2 0 EBV, rhinovirus, BK Mucositis (grade 3)





5 Hep/NAC N 36 Alive 100 100 100 1 0 Bacterial CVL
infection
None












8 Hep Y M DF 40 Y 61 Alive 100 98 98 0 0 N Mucositis, GI problems,
Hashimoto’s
thyroiditis
9 NAC Y M DF 40
paracentesis
Y 15 Alive 100 9 42 0 0 N None




11 Hep Y M DF/steroids Y 88 Alive 100 90 89 0 0 N Mucositis (grade 2)
12 Hep N 111 Alive 100 94 92 1 0 Urinary infection Fever, mucositis (grade
2)
13 None N 45 Alive 100 100 100 1 0 N None
14 NAC N 63 Alive 40 100 98 0 0 N None
15 NAC Y S DF/steroids,
paracentesis,
ventilation




16 NAC Y M DF/steroids Y 31 Alive 100 100 99 1 0 N Recurrent CVL
complications
ADV, adenovirus; aGVHD, acute GVHD; BCG, bacillus Calmette-Guérin; cGVHD, chronic GVHD; CVL, central venous line; DC, donor chimerism; DD, differential diagnosis; DF, defibrotide; EBV, Epstein-Barr virus; FU, follow-up; GI,





















































































































18 NAC Y M DF/steroids/
paracentesis
Y 36 Alive 100 73 30 0 0 N Mucositis (grade 2)
19 NAC, DF 25 N 31 Alive 100 96 87 0 0 N None
20 NAC, DF 25 N 18 Alive 100 58 79 0 0 Metapneumovirus,
HHV-6
None
21 Hep N 14 Alive 100 100 98,5 0 0 Bacterial CVL
infection
Mucositis grade 3
22 None Y M DF Y 22 Alive 100 100 81 0 0 N EBV viremia, rituximab
23 Hep/DF 25 N 8 Alive 100 67 74 0 0 N Mucositis (grade 3),
seizure of unknown
cause
24 NAC N 78 Alive 100 100 100 2 0 N Mucositis (grade 1),
arterial hypertension
25 NAC N 49 Alive 100 97 97 2 0 N Engraftment syndrome,
arthritis of 2 joints
(intra-articular steroid
injections)
ADV, adenovirus; aGVHD, acute GVHD; BCG, bacillus Calmette-Guérin; cGVHD, chronic GVHD; CVL, central venous line; DC, donor chimerism; DD, differential diagnosis; DF, defibrotide; EBV, Epstein-Barr virus; FU, follow-up; GI,








































(UPN2). His quality of life has normalized after bilateral endopros-
thetic hip surgery, with normal pain-free walking.
Eleven patients developed a total of 18 episodes of relevant
infectious reactivations/complications: Epstein-Barr virus (n 5 4),
bacillus Calmette-Guérin infection (n 5 2), BK virus (n 5 2),
rhinovirus (n 5 2), adenovirus (n 5 1), HHV-6 (n 5 1),
metapneumovirus (n 5 1), and fungal (n 5 1) as well as bacterial
infection, including central line (n 5 2), vulva (n 5 1), and urinary
tract (n 5 1). All infectious episodes resolved after specific
treatment and/or reduction of immunosuppression (Table 2).
Discussion
In the past 12 years, several studies have investigated the effect of
RIC/reduced-toxicity regimens and T-cell replete HSCT in patients
with HLH (supplemental Table 1). Despite improved overall
outcomes compared with MAC regimens, several complications
were encountered, including primary/secondary GF, HLH relapses
due to waning DC, and increased incidence of severe acute and
chronic GVHD, mainly after DLI administration to prevent imminent
GF.12,29,31,45-47
In early retrospective single-center studies, melphalan-fludarabine–
based RIC regimens applied mainly in the context of HLA-identical
HSCT achieved OS rates between 80% and 89%; however, high
rates of mixed DC12,31,46 and GF in up to 27% of patients were
observed.45
A reduced-toxicity regimen replacing melphalan with treosulfan in
HLA-compatible transplants including cords achieved an OS rate of
44%.47 Treosulfan (mainly combined with thiotepa) was adminis-
tered in a German multicenter study infusing primarily HLA-
compatible grafts from largely MRD/MUD donors. The OS and
EFS rates improved to 100% and 89%, respectively, but the rate of
secondary cellular treatments remained considerable (42%).29
Finally, in 2018, a prospective US multicenter study investigated 34
treated patients with HLH by using melphalan-fludarabine/RIC
conditioning combined with intermediate-dose alemtuzumab.48 The
18-month OS was 68%, with mixed DC in 65%, grade II to IV acute
GHVD in 26.5%, and chronic GHVD in 32.9% of patients. The
proportion of patients with HLH who were alive with sustained
engraftment without needing secondary cellular therapies was
41.2% (supplemental Table 1).
In the current multicenter study led by the IEWP EBMT, we
administered a busulfan-based RIC protocol and T-cell replete
HLA-identical transplants based on excellent outcome results with
this regimen in high-risk patients with CGD.36,49,50 HLH diagnos-
tics, pretreatment findings, and remission status of the current HLH
cohort were similar to previous studies.26,29,31,48 Unintentionally, no
perforin-, STX11-, or XIAP-deficient patients were among the study
population (supplemental Table 1). The diagnosis of HLH was based
on proven HLH episodes in 19 patients and according to family
history in 3 patients. Two patients with X-linked lymphoproliferative
syndrome 1 presented atypically with acute demyelinating enceph-
alomyelitis or B-cell lymphoma before transplant51 and another with
Chédiak-Higashi syndrome with neurological symptoms. Collection
and treatment of patients in this study led to reproducible results on
the multicenter level after adequate follow-up, which is in agreement
with the recently postulated criteria for transplant studies in HLH.48
After a median follow-up of 36 months post-HSCT, we have not
encountered GF or systemic/CNS HLH relapses. Satisfactory
myeloid and CD31 T-cell DC were achieved with no requirement
for additional cellular therapies, including DLI. The 3-year OS/EFS/
chronic GHVD–free survival rates were excellent with 100%/100%/
95% (CI, 68.12-99.24), respectively (Figure 4).
Our aim was to reduce the previously observed GF rate of 5% with
this RIC regimen36 without adding other alkylating myeloablative
agents. For this purpose, we modified our previous target range of
busulfan toward the upper part of the submyeloablative busulfan
exposure range (45-65 mg/L3 h).37,38,52 Previous reports showed that
myeloablative and toxic properties of busulfan depended on the cAUC,
rendering the total administered busulfan dose irrelevant.36,37,52,53
Here, we observed a wide range of total busulfan doses to achieve the
target cAUC (Figure 1; Table 1), indicating that real-time therapeutic
drug monitoring was important in this protocol. Without real-time
therapeutic drug monitoring, full-dose busulfan might have resulted in
toxic exposures in some patients with slow drug clearance and
insufficient myeloablation in those with rapid drug clearance.52
Fully myeloablative busulfan was previously shown to correspond
with a cAUC of 80 to 100 mg/L 3 h.41 Bartelink et al37 suggested
that a cAUC of 78 to 101 mg/L 3 h was the optimal target for any
patient undergoing HSCT. However, the cohort of Bartelink et al
was heterogeneous and included children with malignant diseases.
We deliberately targeted busulfan to lower exposures to reduce
short-term and gonadal toxicity and to ensure donor cell engraft-
ment in fragile patients with HLH. The approach to target busulfan
within the described submyeloablative exposure was based on
in vitro experiments by Hassan41 and on our previous clinical
experience in patients with CGD.36 Some testable male adolescents
in the former CGD cohort had exhibited preserved fertility while
achieving robust myeloid engraftment (Peter Shaw, Westmead
Hospital Sydney and Rachel Hough, University College Hospital
London, personal communication by telephone and e-mail, 14
November 2014 and 2 June 2015), indicating a reduced gonadal
toxicity in male adolescents receiving this RIC regimen. Whether this
finding is also transposable to female recipients of this RIC regimen is
currently unclear. We believe that long-term toxicity studies on
oocyte/sperm viability after similar submyeloablative busulfan expo-















Figure 2. Engraftment. Primary engraftment of neutrophils (time to reach .0.5 g/
L; red line) and platelets (time to reach .50 g/L; blue line).
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The excellent engraftment presented here has recently been
confirmed in a retrospective series of 12 patients with HLH,
including 2 patients with perforin deficiency (supplemental Table 1).
Richards et al administered once-daily busulfan, fludarabine, and
serotherapy and infused T-cell replete MSD/MUD PBSC donor
transplants as well as UCBs.55 They performed pharmacokinetic
analyses without analyzing the cAUC of busulfan. Retrospective
estimation of the busulfan exposure (Stephanie Richards, De-
partment of Allergy and Immunology, The Royal Children’s Hospital,
personal communication by e-mail 12 May 2019) of their cohort
indicated that the majority of their patients had received busulfan
exposures (cAUC, 45-65 mg/L 3 h) similar to that of the current
study patients. In addition to fludarabine, they administered higher
dose alemtuzumab (up to 3 mg/kg) not later than d-10 before
HSCT. They reported a robust DC .95% at 1 year (one exception
was 82%) and did not administer DLI or stem cell boost infusions.
The OS and EFS of their cohort was 83% and 83%,
respectively. Two patients died of infections early after UCB
transplantation.55
Unexpectedly, the major drawback of our RIC protocol was a rather
high rate of SOS22,25,30 although the overall toxicity of the protocol
was low. Initiated at early clinical signs, therapeutic DF administra-
tion was successful and led to a full resolution of SOS in all affected
patients (Table 2).42,43Most at risk for developing SOSwere infants
,1 year of age (6 of 8 [75%]) who had not received DF prophylaxis.
Two of these were formerly premature infants (UPN11 and UPN15)
(Figure 1; Tables 1 and 2). A prospective study found that DF
prophylaxis in children achieved a 40% reduction of the SOS
incidence, whereas the SOS-associated mortality did not differ
compared with DF-treated control subjects.40 It is noteworthy that
no SOS cases were reported in the cohort of Richards et al,55 who
had used a once-daily busulfan protocol. Previous reports indicate


































































































Figure 3. DC analysis in peripheral blood. (A) Percentages of donor CD151 neutrophils at last follow-up (n 5 25). (B) Percentages of donor CD31 T cells at last follow-
up (n 5 25). (C) Longitudinal analysis of DC in CD151 neutrophils in the first year after HSCT (n 5 14). UPN9 with continuous decrease of neutrophil DC. (D) Longitudinal
analysis of DC in CD31 T cells in the first year after HSCT (n 5 14). UPN9 with continuous increase of CD31 T-cell DC. CD31 T-cell DC ,20% after 6 months (gray area)
increases the risk for relapse of HLH.34 Each symbol depicts 1 patient.
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the SOS incidence and severity in mainly malignant diseases,56,57
but it is conceivable that once-daily administration34,58 could further
reduce the SOS incidence in infants with HLH. Additional
preventive measures to reduce the risk of SOS of our regimen
could include decreasing the cAUC to 55 to 60 mg/L 3 h and/or
the application of a DF prophylaxis in all infants with HLH.40,59,60
The persistence of host CD31 T cells after RIC regimens and viral
reactivations soon after HSCT are both considered risk factors for
the recurrence of HLH.34,61 Hartz et al showed that the percentage
of DC, particularly a CD31 T-cell DC .20% after day 1180 post-
HSCT, was essential for disease control in primary HLH.34 This is in
accordance with animal studies of perforin knockout mice.62 The
investigation of Hartz et al included CD31 T-cell or full blood but not
CD151 myeloid DC analysis.34 Although a minimal threshold level
of donor-derived CD31 T cells was proposed, the minimal level of
CD151myeloid DC to achieve long-term cure of HLH remains to be
determined. Because stable myeloid DC is a prerequisite for long-
term CD31 T-cell production of donor origin, we were encouraged
by the overall stable myeloid DC obtained by using this regimen
(Figure 3A). Regular analysis of both CD31 T-cell and CD151
neutrophil DC in our patients helped us to avoid premature
reduction of immunosuppression and infusion of DLI or administra-
tion of other secondary cellular therapies.29,48,63 Because of
excellent CD151 myeloid DC results, we could accept an
initially mixed donor CD31 T-cell chimerism in some of our patients
(UPN9, UPN18, and UPN23); neither GF nor HLH relapses were
encountered. All viral reactivations were treatable and not
associated with HLH relapses (Table 2). Regular lineage-specific
DC analyses showed that patients with initially mixed CD31 T-cell
DC, CD31 T cells of donor origin gradually increased over the
first year posttransplant, mainly between day 130 and day 1180
but also later (Figure 3D). The fastest gains of CD31 T-cell DC
occurred after cessation of MMF and CSA mainly by rising de novo
production of naive donor-derived CD31 T cells.
Except for UPN9, continuous increases in CD31 T-cell DC and/or
stable CD151 neutrophil DC (Table 2; Figure 3) over time were
standard. A very slow decline of CD151 DC but steadily increasing
CD31 T-cell DC over time were observed in UPN9, with 9%
CD151 neutrophils and 42% CD31 T cells at last follow-up
(15 months post-HSCT). It is noteworthy that even though UPN9 is
considered cured of HLH, we cannot completely exclude a further
decline of myeloid DC in the future.
Lymphocyte depletion via serotherapy is essential for the prevention
of higher grade acute/chronic GVHD. The serotherapy concept of
this protocol presented here had previously been shown to
successfully prevent acute/chronic GHVD; there was no severe
grade II or higher acute GHVD and a 4% incidence of limited
chronic GHVD in patients with CGD transplanted with HLA-
compatible donors.36,49,50 Considering the relative half-life of
alemtuzumab, our dosing regimen (median, 0.6 mg/kg total; d-8
to d-6) was safe and shared properties of the intermediate dosing
scheme of Marsh et al.63 Marsh et al showed that alemtuzumab
dosing and timing substantially influenced DC as well as acute/
chronic GHVD incidence and severity.31,35,63 Intermediate dosing
of alemtuzumab (1 mg/kg; d-14 to d-10) led to lower mixed DC
rates (31%) than proximal dosing (1 mg/kg; d-8/9 to d-4/5) (72%)
or distal dosing ($2 mg/kg; d-22 to d-19) (75%).35 Given the
variability of inflammation and lymphocyte count before transplant,
a more precise pharmacokinetic approach toward pretransplant
alemtuzumab levels could be helpful to further improve or individualize
dosing64 in the future.
Another potential cause for the low prevalence of acute/chronic
GHVD observed in the current study was the preference of HSC
from bone marrow/CB over PBSC sources. The introduction of
T cell–depleted PBSCs with CD31 T-cell addback in unrelated
single allele mismatch PBSC donors may have been additionally
GHVD preventive.39 The latter technique has been applied in 3
patients (UPN17, UPN21, and UPN25), adjusting the CD31 T-cell
content of their grafts to average bone marrow CD31 T-cell
contents. Interestingly, the sole event of reversible limited chronic
GHVD still occurred in a patient (UPN17) treated with this
technique after a 9/10-HLA–matched PBSC transplant. This
outcome indicates that patients with single allele mismatch PBSC
transplants could benefit from more rigorous in vivo and in vitro
CD31 T-cell depletion techniques; however, this would be at the
expense of risking insufficient engraftment due to insufficient graft-
versus-marrow effect.
This multicenter investigation found high cure rates and successful
prevention of GF and GVHD in patients with various types of HLH.
Sufficient myeloid and CD31 T-cell donor cell engraftment was
achieved without applying secondary cellular treatments. Targeted
busulfan administration within the analyzed range achieved curative
myeloid DC, rendering the administration of other alkylating agents
unnecessary. The reduction of the cAUC of busulfan by ;20% to
35% was sufficiently myeloablative, and the overall toxicity was low.
Nevertheless, some infants developed SOS that was successfully
treated with DF. Lower cumulative busulfan exposures, modification of
busulfan application (once-daily infusion), and DF prophylaxis in infants
could further reduce the risk for SOS. After sufficient follow-up,
satisfactory donor CD151myeloid, CD31 T-cell, and NK cell DCwere
achieved, and relapses of HLH in blood and CNS were successfully
prevented.65 Because no perforin-, STX11-, and XIAP-deficient
patients were treated with the current RIC regimen, more experience
with this protocol in these forms of HLH is mandatory. The analysis of
long-term cure and fertility should be objectives of future studies.















Figure 4. OS/EFS and chronic GHVD-free survival. The OS/EFS (red line) and
1-year OS/EFS probabilities (100%) and the chronic GHVD-free survival (blue line)
and 1-year GFS probability (95% confidence interval, 68.12-99.24) are shown.
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17. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer.
2007;48(2):124-131.
18. Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins:
a single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622-e628.
2008 FELBER et al 12 MAY 2020 x VOLUME 4, NUMBER 9
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36. Güngör T, Teira P, Slatter M, et al; Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Reduced-intensity
conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Lancet. 2014;383(9915):436-448.
37. Bartelink IH, Lalmohamed A, van Reij EM, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in
children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3(11):e526-e536.
38. Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation
patients: towards individualized dosing. Clin Pharmacokinet. 2012;51(5):331-345.
39. Seitz CM, Eyrich M, Greil J, et al. Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts.
Bone Marrow Transplant. 2019;54(1):53-62.
40. Corbacioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell
transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379(9823):1301-1309.
41. Hassan Z. Optimal approach to prevent veno-occlusive disease following hematopoietic stem cell transplantation in children. Pediatr Transplant. 2010;
14(6):683-687.
42. Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of
pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006;91(6):795-800.
43. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study
demonstrates therapeutic efficacy upon early intervention [published correction appears in Bone Marrow Transplant. 2004;33(6):673]. Bone Marrow
Transplant. 2004;33(2):189-195.
44. Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric
patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138-145.
45. Nishi M, Nishimura R, Suzuki N, et al. Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic
lymphohistiocytosis. Am J Hematol. 2012;87(6):637-639.
12 MAY 2020 x VOLUME 4, NUMBER 9 BUSULFAN-BASED RIC AND HLA-MATCHED HSCT CURE HLH 2009
46. Hamidieh AA, Pourpak Z, Hashemi S, et al. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in
primary hemophagocytic lymphohistiocytosis. Eur J Haematol. 2014;92(4):331-336.
47. Slatter MA, Rao K, Abd Hamid IJ, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary
immunodeficiency: UK experience. Biol Blood Marrow Transplant. 2018;24(3):529-536.
48. Allen CE, Marsh R, Dawson P, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood.
2018;132(13):1438-1451.
49. Freudenberg F, Wintergerst U, Roesen-Wolff A, et al. Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as
inflammatory bowel disease. J Allergy Clin Immunol. 2010;125(4):943-946.e1.
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